公开(公告)号：JP2013224297A

公开(公告)日：2013-10-31

申请号：JP2013117575

申请日：2013-06-04

Applicant: Abbott Lab ,  アボット・ラボラトリーズAbbott Laboratories

Inventor： KRILL STEVEN K ,  FORT JAMES J ,  LAW DEVALINA ,  SCHMITT ERIC A ,  QIU YIHONG

IPC: A61K31/427 ,  A61K47/32 ,  A61K9/16 ,  A61K9/20 ,  A61K9/48 ,  A61K31/216 ,  A61K31/343 ,  A61K31/513 ,  A61K45/00 ,  A61K47/10 ,  A61K47/14 ,  A61K47/34 ,  A61K47/38 ,  A61P3/06 ,  A61P31/10 ,  A61P31/18 ,  A61P43/00

CPC classification number: A61K9/1635 ,  A61K9/1652 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/4866 ,  A61K31/427 ,  A61K31/497

Abstract: PROBLEM TO BE SOLVED: To provide novel solid dispersion pharmaceutical formulations which demonstrate an inhibition of crystallization.SOLUTION: A solid pharmaceutical composition contains: a molecular dispersion of ritonavir (ABT-538); a hydrophilic, amorphous polymer selected from the group consisting of polyvinylpyrrolidone (PVP) and hydroxypropylmethylcellulose (HPMC); and matrix comprising a water soluble carrier which is selected from the group consisting of polyethylene glycol (PEG), pentaerythritol, pentaerythritol tetraacetate, polyoxyethylene stearate, and poly-ε-caprolacton. The matrix includes an amorphous region where the ritonavir resides.

Abstract translation: 要解决的问题：提供显示抑制结晶的新型固体分散体药物制剂。溶液：固体药物组合物含有：利托那韦（ABT-538）的分子分散体; 选自聚乙烯吡咯烷酮（PVP）和羟丙基甲基纤维素（HPMC）的亲水性无定形聚合物; 和包含选自聚乙二醇（PEG），季戊四醇，四乙酸季戊四醇酯，聚氧乙烯硬脂酸酯和聚ε-己内酯的水溶性载体的基质。 该基质包括利托那韦所在的无定形区域。

公开(公告)号：WO0134118A3

公开(公告)日：2002-01-10

申请号：PCT/US0030910

申请日：2000-11-10

Applicant: ABBOTT LAB

Inventor： FORT JAMES J ,  KRILL STEVEN L ,  LAW DEVALINA ,  QIU YIHONG ,  PORTER WILLIAM R ,  SCHMITT ERIC A

IPC: A61K9/20 ,  A61K9/14 ,  A61K9/48 ,  A61K31/00 ,  A61K31/425 ,  A61K31/427 ,  A61K31/47 ,  A61K31/495 ,  A61K31/505 ,  A61K45/00 ,  A61K47/10 ,  A61K47/34 ,  A61P31/18 ,  A61K31/513

CPC classification number: A61K31/495 ,  A61K9/146 ,  A61K31/00 ,  A61K31/425 ,  A61K31/47

Abstract: A pharmaceutical composition is disclosed which comprises a soliddispersion of an HIV protease inhibitor in a water soluble carrier, such as PEG, having enhanced bioavailability and improved dissolution properties. The solid dispersion may optionally be encapsulated in hard gelatin capsules, compressed into a tablet, or may be granulated with a pharmaceutically acceptable granulating agent. Also disclosed are methods of making said solid dispersion and methods of treating an HIV infection employing said solid dispersion.

Abstract translation: 公开了一种药物组合物，其包含在水溶性载体例如PEG中的HIV蛋白酶抑制剂的固体分散体，其具有增强的生物利用度和改善的溶出性质。 固体分散体可以任选地包封在硬明胶胶囊中，压制成片剂，或者可以用药学上可接受的制粒剂造粒。 还公开了制备所述固体分散体的方法和使用所述固体分散体治疗HIV感染的方法。

公开(公告)号：WO0134119A3

公开(公告)日：2001-11-22

申请号：PCT/US0031072

申请日：2000-11-10

Applicant: ABBOTT LAB

Inventor： KRILL STEVEN K ,  FORT JAMES J ,  LAW DEVALINA ,  SCHMITT ERIC A ,  QIU YIHONG

IPC: A61K47/32 ,  A61K9/16 ,  A61K9/20 ,  A61K9/48 ,  A61K31/216 ,  A61K31/343 ,  A61K31/427 ,  A61K31/513 ,  A61K45/00 ,  A61K47/38 ,  A61P3/06 ,  A61P31/10 ,  A61P43/00 ,  A61K9/14 ,  A61P31/18

CPC classification number: A61K9/1635 ,  A61K9/1652 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/4866 ,  A61K31/427 ,  A61K31/497

Abstract: A pharmaceutical composition is disclosed which comprises a solid dispersion of a pharmaceutical compound in a water soluble carrier, such as polyethylene glycol (PEG), and a crystallization inhibitor, such as polyvinylpyrrolidone or hydroxypropylmethylcellulose. The solid dispersion may optionally be encapsulated in hard gelatin capsules, compressed into a tablet, or may be granulated wiht a pharmaceutically acceptable granulating agent. Also disclosed are methods of making said solid dispersion and methods of treatment employing said solid dispersion.

Abstract translation: 公开了药物组合物，其包含药物化合物在水溶性载体如聚乙二醇（PEG）中的固体分散体和结晶抑制剂如聚乙烯吡咯烷酮或羟丙基甲基纤维素。 该固体分散体可以任选地被包封在硬明胶胶囊中，压制成片剂，或者可以用药学上可接受的成粒剂造粒。 还公开了制备所述固体分散体的方法和使用所述固体分散体的处理方法。

公开(公告)号：WO0134119A9

公开(公告)日：2002-09-26

申请号：PCT/US0031072

申请日：2000-11-10

Applicant: ABBOTT LAB

Inventor： KRILL STEVEN K ,  FORT JAMES J ,  LAW DEVALINA ,  SCHMITT ERIC A ,  QIU YIHONG

IPC: A61K47/32 ,  A61K9/16 ,  A61K9/20 ,  A61K9/48 ,  A61K31/216 ,  A61K31/343 ,  A61K31/427 ,  A61K31/513 ,  A61K45/00 ,  A61K47/38 ,  A61P3/06 ,  A61P31/10 ,  A61P43/00 ,  A61K9/14 ,  A61P31/18

CPC classification number: A61K9/1635 ,  A61K9/1652 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/4866 ,  A61K31/427 ,  A61K31/497

Abstract: A pharmaceutical composition is disclosed which comprises a solid dispersion of a pharmaceutical compound in a water soluble carrier, such as polyethylene glycol (PEG), and a crystallization inhibitor, such as polyvinylpyrrolidone or hydroxypropylmethylcellulose. The solid dispersion may optionally be encapsulated in hard gelatin capsules, compressed into a tablet, or may be granulated wiht a pharmaceutically acceptable granulating agent. Also disclosed are methods of making said solid dispersion and methods of treatment employing said solid dispersion.

Abstract translation: 公开了一种药物组合物，其包含药物化合物在水溶性载体如聚乙二醇（PEG）和结晶抑制剂如聚乙烯吡咯烷酮或羟丙基甲基纤维素中的固体分散体。 固体分散体可以任选地包封在硬明胶胶囊中，压制成片剂，或者可以用药学上可接受的造粒剂造粒。 还公开了制备所述固体分散体的方法和使用所述固体分散体的处理方法。

公开(公告)号：WO0174787A3

公开(公告)日：2002-02-07

申请号：PCT/US0109112

申请日：2001-03-21

Applicant: ABBOTT LAB

Inventor： DICKMAN DANIEL A ,  CHEMBURKAR SANJAY ,  FORT JAMES J ,  HENRY RODGER F ,  LECHUGA-BALLESTEROS DAVID ,  NIU YUPING ,  PORTER WILLIAM

IPC: A61K31/513 ,  A61P31/18 ,  A61P43/00 ,  C07D239/10 ,  A61K31/505

CPC classification number: C07D239/10

Abstract: New crystalline forms of lopinavir are disclosed.

Abstract translation: 公开了新的结晶形式的洛匹那韦。

公开(公告)号：PL359727A1

公开(公告)日：2004-09-06

申请号：PL35972701

申请日：2001-03-21

Applicant: ABBOTT LAB

Inventor： DICKMAN DANIEL A ,  CHEMBURKAR SANJAY ,  FORT JAMES J ,  HENRY RODGER F ,  LECHUGA-BALLESTEROS DAVID ,  NIU YUPING ,  PORTER WILLIAM

IPC: A61K20060101 ,  A61K31/513 ,  A61P20060101 ,  A61P31/18 ,  A61P43/00 ,  C07D20060101 ,  C07D239/10 ,  A61K31/505

Abstract: New crystalline forms of lopinavir are disclosed.

公开(公告)号：BR0109433A

公开(公告)日：2004-08-10

申请号：BR0109433

申请日：2001-03-21

Applicant: ABBOTT LAB

Inventor： DICKMAN DANIELA A ,  CHEMBURKAR SANJAY ,  FORT JAMES J ,  HENRY RODGER F ,  LECHUGA-BALLESTEROS DAVID ,  NIU YUPING ,  PORTER WILLIAM

IPC: A61K20060101 ,  A61K31/513 ,  A61P20060101 ,  A61P31/18 ,  A61P43/00 ,  C07D20060101 ,  C07D239/10 ,  C07D239/00

Abstract: New crystalline forms of lopinavir are disclosed.

公开(公告)号：NO20024679A

公开(公告)日：2002-09-30

申请号：NO20024679

申请日：2002-09-30

Applicant: ABBOTT LAB

Inventor： DICKMAN DANIEL A ,  CHEMBURKAR SANJAY ,  FORT JAMES J ,  HENRY RODGER F ,  LECHUGA-BALLESTEROS DAVID ,  NIU YUPING ,  PORTER WILLIAM

IPC: A61K31/513 ,  A61P31/18 ,  A61P43/00 ,  C07D239/10

CPC classification number: C07D239/10

公开(公告)号：PE12322001A1

公开(公告)日：2001-12-08

申请号：PE0002992001

申请日：2001-03-30

Applicant: ABBOTT LAB

Inventor： DICKMAN DANIEL A ,  CHEMBURKAR SANJAY ,  HENRY RODGER F ,  NIU YUPING ,  PORTER WILLIAM ,  LECHUGA-BALLESTEROS DAVID ,  FORT JAMES J

IPC: A61K31/513 ,  A61P31/18 ,  A61P43/00 ,  C07D239/00 ,  C07D239/10

CPC classification number: C07D239/10

Abstract: SE REFIERE A LA FORMA CRISTALINA HIDRATADA O SOLVATADA DE LOPINAVIR (2S,3S,5S)-2-(2,6-DIMETILFENOXIACETIL)AMIN-3-HIDROXI-5-(2-(1-TETRAHIDROPIRIMID-2-ONIL)-3-METILBUTANOL)AMIN-1,6-DIFENILHEXANO) DE FORMULA I CARACTERIZADA POR PRESENTAR UN ESPECTRO INFRARROJO; UN PATRON DE DIFRACCION DE RAYOS X. EL LOPINAVIR ES UN INHIBIDOR DE PROTEASA DEL VIH

公开(公告)号：CA2390092C

公开(公告)日：2009-07-14

申请号：CA2390092

申请日：2000-11-10

Applicant: ABBOTT LAB

Inventor： SCHMITT ERIC A ,  LAW DEVALINA ,  PORTER WILLIAM R ,  QIU YIHONG ,  KRILL STEVEN L ,  FORT JAMES J

IPC: A61K9/20 ,  A61K31/513 ,  A61K9/14 ,  A61K9/48 ,  A61K31/00 ,  A61K31/425 ,  A61K31/427 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/472 ,  A61K31/495 ,  A61K31/496 ,  A61K31/505 ,  A61K45/00 ,  A61K47/10 ,  A61K47/34 ,  A61P31/18

Abstract: A pharmaceutical composition is disclosed which comprises a soliddispersion of an HIV protease inhibitor in a water soluble carrier, such as PEG, having enhanced bioavailability and improved dissolution properties. The solid dispersion may op-tionally be encapsulated in hard gelatin capsules, compressed into a tablet, or may be granulated with a pharmaceutically acceptable granulating agent. Also disclosed are methods of making said solid dispersio n and methods of treating an HIV infection employing said solid dispersion.